Ivan Praznovec
Overview
Explore the profile of Ivan Praznovec including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
10
Citations
317
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Pattern of pelvic recurrence in MRI-only adaptive brachytherapy for locally advanced cervical cancer
Pohankova D, Sirak I, Hodek M, Kasaova L, Paluska P, Grepl J, et al.
Brachytherapy
. 2024 Nov;
24(1):11-17.
PMID: 39613706
Purpose: MRI-only adaptive brachytherapy (MRI-ABT) is the state-of-the-art for treating locally advanced cervical cancer (LACC) in combination with concurrent chemoradiotherapy. We aimed to evaluate the pattern of pelvic recurrence after...
2.
Lanickova T, Hensler M, Kasikova L, Vosahlikova S, Angelidou A, Pasulka J, et al.
Clin Cancer Res
. 2024 Aug;
31(1):164-180.
PMID: 39163092
Purpose: Patients with high-grade serous ovarian carcinoma (HGSOC) are virtually insensitive to immune checkpoint inhibitors (ICI) employed as standalone therapeutics, at least in part reflecting microenvironmental immunosuppression. Thus, conventional chemotherapeutics...
3.
Kasikova L, Rakova J, Hensler M, Lanickova T, Tomankova J, Pasulka J, et al.
Nat Commun
. 2024 Mar;
15(1):2528.
PMID: 38514660
Intratumoral tertiary lymphoid structures (TLSs) have been associated with improved outcome in various cohorts of patients with cancer, reflecting their contribution to the development of tumor-targeting immunity. Here, we demonstrate...
4.
Pavelkova L, Taborska E, Syding L, Plackova K, Simonova E, Hladikova K, et al.
Transl Oncol
. 2024 Jan;
41:101884.
PMID: 38242007
The profile of the antitumor immune response is an important factor determining patient clinical outcome. However, the influence of the tissue contexture on the composition of the tumor microenvironments of...
5.
Fucikova J, Hensler M, Kasikova L, Lanickova T, Pasulka J, Rakova J, et al.
Clin Cancer Res
. 2022 May;
28(14):3053-3065.
PMID: 35536547
Purpose: The successful implementation of immune checkpoint inhibitors (ICI) in the clinical management of various solid tumors has raised considerable expectations for patients with epithelial ovarian carcinoma (EOC). However, EOC...
6.
Ndukwe M, Praznovec I, Stepan M, Sirak I, Fibir A, Spacek J
Ceska Gynekol
. 2021 Sep;
86(4):246-248.
PMID: 34493049
Objective: Summarizing of treatment options for locally recurrent vulvar cancer in patients after previous complex oncological treatment and presenting a case report from our department. Methods: Presenting a case report...
7.
Hensler M, Kasikova L, Fiser K, Rakova J, Skapa P, Laco J, et al.
J Immunother Cancer
. 2020 Aug;
8(2).
PMID: 32819974
Background: The immunological microenvironment of primary high-grade serous carcinomas (HGSCs) has a major impact on disease outcome. Conversely, little is known on the microenvironment of metastatic HGSCs and its potential...
8.
Kasikova L, Hensler M, Truxova I, Skapa P, Laco J, Belicova L, et al.
J Immunother Cancer
. 2019 Nov;
7(1):312.
PMID: 31747968
Background: Adjuvanticity, which is the ability of neoplastic cells to deliver danger signals, is critical for the host immune system to mount spontaneous and therapy-driven anticancer immune responses. One of...
9.
Fucikova J, Rakova J, Hensler M, Kasikova L, Belicova L, Hladikova K, et al.
Clin Cancer Res
. 2019 May;
25(15):4820-4831.
PMID: 31076549
Purpose: In multiple oncological settings, expression of the coinhibitory ligand PD-L1 by malignant cells and tumor infiltration by immune cells expressing coinhibitory receptors such as PD-1, CTLA4, LAG-3, or TIM-3...
10.
Truxova I, Kasikova L, Hensler M, Skapa P, Laco J, Pecen L, et al.
J Immunother Cancer
. 2018 Dec;
6(1):139.
PMID: 30526667
A high density of tumor-infiltrating CD8 T cells and CD20 B cells correlates with prolonged survival in patients with a wide variety of human cancers, including high-grade serous ovarian carcinoma...